In a patient with acute ischemic stroke and known coronary artery disease (e.g., recent percutaneous coronary intervention with stent), what antiplatelet regimen and timing should be used for stroke secondary prevention while respecting the coronary dual antiplatelet therapy requirements?

Antiplatelet Therapy in Coronary Artery Disease with Acute Ischemic Stroke

Initial Management: First 24–48 Hours

For patients with acute ischemic stroke and known coronary artery disease (especially recent PCI with stent), continue dual antiplatelet therapy (aspirin + clopidogrel) without interruption if the stroke is minor (NIHSS ≤3), but obtain urgent neuroimaging to exclude intracranial hemorrhage before any antiplatelet decision. 1

Immediate Assessment Protocol

• Obtain urgent non-contrast CT or MRI within minutes of presentation to exclude intracranial hemorrhage before continuing or initiating any antiplatelet therapy. 1, 2
• Assess stroke severity using NIHSS score: minor stroke = NIHSS ≤3; moderate-to-severe = NIHSS >3. 1, 2
• Determine timing: if patient received IV alteplase, all antiplatelet agents must be held for 24 hours post-thrombolysis with repeat imaging to confirm no hemorrhagic transformation. 3, 1, 2

Decision Algorithm Based on Stroke Severity

Minor Stroke (NIHSS ≤3) with Recent PCI/Stent:

• Continue existing dual antiplatelet therapy (aspirin + clopidogrel) without interruption if the patient is already on DAPT for coronary indications and neuroimaging excludes hemorrhage. 1, 4
• Loading doses are NOT required when restarting after a brief hold (1–2 days); resume maintenance dosing only: aspirin 75–100 mg daily + clopidogrel 75 mg daily. 1
• Duration: Continue DAPT for the full duration required by the coronary indication (typically 12 months for drug-eluting stent), which takes precedence over the 21-day stroke protocol. 1, 4

Moderate-to-Severe Stroke (NIHSS >3) with Recent PCI/Stent:

• This creates a high-risk scenario requiring urgent cardiology consultation because continuing DAPT increases hemorrhagic transformation risk, but stopping it risks stent thrombosis. 4, 2
• If <30 days post-stent placement: strongly favor continuing DAPT despite stroke severity, as stent thrombosis risk is prohibitively high. 1
• If >30 days post-stent placement: consider transitioning to aspirin monotherapy (160–325 mg loading, then 75–100 mg daily) after multidisciplinary discussion weighing stroke hemorrhagic risk against cardiac ischemic risk. 1, 2

Special Scenario: Stroke While Already on DAPT for Coronary Disease

If stroke occurs despite existing DAPT, this suggests inadequate antiplatelet effect is unlikely; the underlying pathology is high-risk vascular disease rather than treatment failure. 1

• Do NOT add a third antiplatelet agent (e.g., do not add ticagrelor to aspirin + clopidogrel). 1, 2
• Do NOT reload clopidogrel if the patient was already taking it; continue maintenance dose 75 mg daily. 1
• Continue existing DAPT regimen (aspirin 75–100 mg + clopidogrel 75 mg daily) for the full coronary-indicated duration. 1, 4

Timing Considerations After Thrombolysis

If IV alteplase was administered:

• Hold all antiplatelet agents for minimum 24 hours post-thrombolysis. 3, 1, 2
• Obtain repeat CT/MRI at 24 hours to exclude hemorrhagic transformation before restarting antiplatelet therapy. 1, 2
• Resume maintenance doses only (no loading): aspirin 75–100 mg + clopidogrel 75 mg daily. 1

Long-Term Management After Acute Phase

After completing the coronary-mandated DAPT duration (typically 12 months post-stent):

• Transition to single antiplatelet therapy for stroke secondary prevention: aspirin 75–100 mg daily OR clopidogrel 75 mg daily. 1, 2, 5
• Clopidogrel 75 mg daily is preferred over aspirin in patients with diabetes, peripheral arterial disease, or aspirin intolerance. 1, 5
• Do NOT continue long-term DAPT beyond the coronary indication as bleeding risk (hazard ratio 2.22–2.32) outweighs stroke prevention benefit. 1, 6

Critical Safety Warnings

• Never use DAPT as a substitute for thrombolysis or thrombectomy in eligible patients; antiplatelet therapy does not replace reperfusion strategies. 1, 2
• Never use glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) in acute ischemic stroke; they are potentially harmful. 1, 2
• Never substitute ticagrelor for clopidogrel in the acute stroke setting; ticagrelor increases intracranial hemorrhage risk and is not recommended. 1, 2
• Monitor for bleeding complications throughout DAPT duration; consider proton-pump inhibitor prophylaxis for gastrointestinal protection. 1

Evidence Quality

The recommendation to continue DAPT in minor stroke with recent coronary stenting is based on consensus expert opinion balancing stroke hemorrhagic risk against stent thrombosis risk, as randomized trials specifically excluded patients with recent PCI. 1, 4 The 21-day DAPT protocol for minor stroke is supported by Class I, Level A evidence from CHANCE and POINT trials, but these trials excluded patients with mandatory cardiac DAPT indications. 1, 4, 6, 7